Bharat Biotech says 'Covaxin effective against Covid strains found in India, UK'
Total Views |
New Delhi, May 17: At the time when WHO has expressed the concern over the new COVID strain found in India, the Bharat Biotech has announced that their Made In India COVID vaccine 'COVAXIN' has shown efficiency against the new covid strains found in the UK and India.
Citing a study report published in medical journal clinical infectious diseases, the company underlined that, Covaxin successfully neutralized all key emerging variants tested including- the double mutant strain B.1.617 and B.1.1.
The joint managing director of Bharat Biotech, Suchitra Ella tweeted the report on her social media wall. She tweeted, "Covaxin gets international recognition yet again, by scientific research data published demonstrating protection against the new variants. Yet another feather in its cap."
Hyderabad-based-vaccine manufacturer further noted that the modest reduction in neutralisation by a factor of 1.95 against B.1.617 variant compared to vaccine variant D614G. Despite this reduction, neutralizing titer levels with B.1.617 remain above levels expected to be protective, it added.
The study was conducted by the National Institute of Virology and the India Council of Medical Research.
Earlier, the director of the U.S. National Institute of Allergy and Infectious Diseases and the chief medical advisor to the president Anthony Fauci also praised the indigenous vaccines saying it neutralizes 63 covid variants.
Last week, the Drugs Controller General of India gave its approval to Covaxin for conducting Phase 2-3 trials on 2-18-year-olds in India. The trials are expected to be completed in the next 2-3 months.
.
.